Voyager Therapeutics (VYGR) awards 50,000 RSUs to legal chief

Rhea-AI Filing Summary

Shiferman Gregory L. reported acquisition or exercise transactions in this Form 4 filing.

Voyager Therapeutics, Inc. granted 50,000 restricted stock units (RSUs) to SVP and General Counsel Gregory L. Shiferman as equity compensation. Each RSU represents one share of common stock upon vesting.

The award was granted on April 1, 2026 under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The RSUs vest over three years: one-third on the first anniversary of the grant date and one-third on each of the next two anniversaries, contingent on his continued service. After this grant, he holds 50,000 shares/RSUs directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shiferman Gregory L.

Role SVP and General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,000	$0.00	--

Holdings After Transaction: Common Stock — 50,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 50,000 RSUs Grant price per share: $0.0000 per share Post-grant holdings: 50,000 shares/RSUs +1 more

4 metrics

RSU grant size 50,000 RSUs Equity award to SVP and General Counsel on April 1, 2026

Grant price per share $0.0000 per share Compensation grant, not an open-market purchase

Post-grant holdings 50,000 shares/RSUs Total direct holdings following the reported transaction

Vesting period 3 years RSUs vest in three equal annual installments from April 1, 2026

Key Terms

restricted stock units, vesting commencement date, 2025 Stock Incentive Plan, continued service

4 terms

restricted stock units financial

"Consists of shares of common stock issuable under an aggregate of 50,000 restricted stock units ("RSUs")"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting commencement date financial

"The vesting commencement date of the RSU award is the grant date, April 1, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

2025 Stock Incentive Plan financial

"awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan")."

continued service financial

"thereafter, subject to the Reporting Person's continued service."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shiferman Gregory L.

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP and General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		50,000(1)	A	$0.00	50,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of shares of common stock issuable under an aggregate of 50,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, April 1, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

	/s/ Gregory L. Shiferman	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Voyager Therapeutics (VYGR) report for Gregory L. Shiferman?

Gregory L. Shiferman received 50,000 restricted stock units from Voyager Therapeutics as an equity grant. These RSUs were awarded under the 2025 Stock Incentive Plan and represent potential future shares of common stock, subject to a multi-year vesting schedule tied to continued service.

How many Voyager Therapeutics (VYGR) shares are covered by the new RSU grant?

The RSU grant covers 50,000 shares of Voyager Therapeutics common stock. Each restricted stock unit converts into one share upon vesting, so full vesting would give Gregory L. Shiferman 50,000 shares, assuming all vesting conditions based on continued service are satisfied.

What is the vesting schedule for Gregory L. Shiferman’s 50,000 Voyager (VYGR) RSUs?

The 50,000 RSUs vest over three years starting April 1, 2026. One-third vests on the first anniversary of that date, and the remaining two-thirds vest in equal one-third installments at the end of each successive one-year period, subject to continued service.

Did Gregory L. Shiferman pay anything for his Voyager Therapeutics (VYGR) RSU award?

The RSU award was reported at a price of $0.0000 per share, indicating it was a compensation grant rather than a purchase. He did not buy these shares on the open market; they are equity incentives under the company’s 2025 Stock Incentive Plan.

What is Gregory L. Shiferman’s position at Voyager Therapeutics (VYGR)?

Gregory L. Shiferman serves as Senior Vice President and General Counsel at Voyager Therapeutics. The reported RSU grant aligns his compensation partly with the company’s stock, linking his long-term incentives to Voyager’s share performance and his continued service.

How many Voyager Therapeutics (VYGR) shares does Gregory L. Shiferman hold after this RSU grant?

Following the reported transaction, Gregory L. Shiferman is shown holding 50,000 shares/RSUs directly. This reflects the full 50,000 restricted stock units granted, which will convert into common shares only as the award vests over the three-year schedule.